Lab Product News
News

$4.7M grant supports Crohn’s disease trial


London, ON – Robarts Research Institute says that contract research organization Robarts Clinical Trials has been awarded a $4.7 million grant to conduct a randomized controlled trial evaluating treatment options for Crohn’s disease.

The outcome is expected to lead to a more streamlined treatment path and better disease management for patients. Abbott, the global health care company, has provided a grant to complete research for the REACT (Randomized Evaluation of an Algorithm for Crohn’s Treatment) study.

The REACT study will be carried out at 40 gastroenterology practices in Canada and Belgium. The sites will be randomly assigned to treat patients with Crohn’s disease to either a conventional management strategy featuring gradual escalation of drug therapy or a newer paradigm that features early use of combined immunosuppression with a tumor necrosis factor alpha blocking drug and an anti-metabolite.

“This trial builds on the results of recent studies that suggest use of combined therapy early in the course of treatment yields superior long-term results,” says Dr Brian Feagan, the lead investigator for the study. “We are excited about this project since it is the first large-scale, community-based evaluation of this approach. We expect that patients treated with combination therapy will be more likely to enter remission and rates of hospitalization and health-care utilization will be reduced.”

Dr Feagan is the director of Robarts Clinical Trials and a professor in the department of medicine at Western’s Schulich School of Medicine & Dentistry.